Table. 3.

The Efficacy of Recombinant Adjuvant Subunit Vaccine (Shingrix®) in Adults Grouped by Age

Characteristic ZOE-50 ZOE-70
Study population n = 14,411Age: ≥ 50 yr n = 13,900Age: ≥ 70 yr
Median follow-up 3.2 yr 3.7 yr
HZ risk reduction (%) Overall: 97.2 Overall: 89.8
50-59 yr: 96.6
60-69 yr: 97.4
≥ 70 yr: 97.9
PHN risk reduction (%) ≥ 50 yr: 91.2 ≥ 70 yr: 88
Vaccine-related SAE n = 1 (vs. n = 3 in placebo) n = 12 (vs. n = 8 in placebo)

ZOE: study done on the efficacy and safety of the herpes zoster recombinant subunit vaccine, HZ: herpes zoster, PHN: postherpetic neuralgia, SAE: systemic adverse effects.

Korean J Pain 2020;33:201~207 https://doi.org/10.3344/kjp.2020.33.3.201
© Korean J Pain